Business Context and Reporting Period
This Form 8-K, dated October 14, 2022, is filed by East Resources Acquisition Company (ERES), a Delaware corporation and emerging growth company. The filing reports the entry into a material definitive agreement regarding a proposed business combination with Abacus Global Management, Inc. (specifically its subsidiaries Longevity Market Assets, LLC and Abacus Settlements, LLC, collectively the "Companies").
Key Financial Metrics and Transaction Terms
The filing details the financial structure of the proposed merger through an amendment to the original Merger Agreement dated August 30, 2022. Key transaction metrics include:
- Company Member Value: Defined as $618,000,000 minus $86,250,000, resulting in a net value of $531,750,000.
- Stock Consideration: Assuming zero cash consideration, the transaction will result in the issuance of 53,175,000 shares of ERES Class A common stock to the Company Members.
- Valuation Basis: The stock consideration is calculated by dividing the Company Member Value by $10.00 per share.
- Operating Metrics: The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the Companies or ERES for any reporting period.
Material Changes Versus Prior Period
The primary material change reported is the execution of the First Amendment to the Agreement and Plan of Merger. This amendment modifies the original agreement in the following ways:
- Valuation Clarification: Explicitly defines the Company Member Value calculation ($618M less $86.25M).
- Stock Consideration Formula: Restates the definition to clarify the share issuance formula based on the net value divided by $10.00.
- Tax Treatment: Clarifies the intended tax treatment of the transactions and related representations.
- Regulatory Condition Removal: Removes the requirement for Abacus to be relicensed as a life settlement provider by the California Department of Insurance prior to closing.
Guidance, Outlook, Risks, and Contingencies
The filing contains extensive forward-looking statements regarding the anticipated benefits, timing, and financial performance of the combined entity. However, it explicitly states that these are not guarantees. Key risks and contingencies identified include:
- Transaction Completion: Risks that the merger may not be completed in a timely manner, may fail to meet the business combination deadline, or may be terminated.
- Approvals and Conditions: The transaction is contingent upon stockholder approvals, regulatory approvals, and meeting minimum aggregate transaction proceeds following potential redemptions.
- Industry Risks: Specific risks related to the life settlement industry, including premium cost increases, insured longevity, and legal challenges by insurers regarding policy validity.
- Operational Risks: Potential disruption to business operations, difficulty in retaining employees, and challenges in managing growth post-merger.
- Valuation Uncertainty: The filing notes a lack of a third-party valuation in determining the pursuit of the transactions.
Important Facts for Investor Verification
- Verify the final number of shares to be issued, which depends on the final determination of cash consideration versus the $531,750,000 net value.
- Confirm the status of the minimum aggregate transaction proceeds requirement and the potential impact of stockholder redemptions on deal viability.
- Review the upcoming Proxy Statement for detailed risk factors and the full list of participants in the solicitation.
- Monitor the status of required governmental and regulatory approvals, noting the removal of the specific California relicensing condition.
- Assess the impact of the $86,250,000 deduction from the gross valuation on the final equity stake received by the target company owners.